Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
- Conditions
- Haematologic DiseaseHaematological Malignancy
- Interventions
- Other: clinical data and sample collection
- Registration Number
- NCT04298892
- Brief Summary
Exploratory multicenter, non-interventional, translational, retrospective and prospective study. All patients with a diagnosis of hematologic disorder or malignancy for whom biological samples and clinical data are available may be included in this study, after obtaining informed consent
- Detailed Description
Hematological malignancies account for approximately 9.5% of newly diagnosed cancers every year and their incidence shows an exponential rise after the age of 40. Since life expectancy is dramatically and continuously increasing worldwide, hematological diseases promise to become a substantial burden for the health care systems of the European society. The management of hematological malignancies is further complicated by the high level of disease heterogeneity in terms of pathogenic and molecular mechanisms. Due to the high level of heterogeneity in terms of cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional and metabolic alterations, an accurate molecular classification of hematological diseases is needed to improve clinical outcomes and patients' management. This is an exploratory multicenter, non-interventional, translational, retrospective and prospective study. All patients with a diagnosis of hematologic disorder or malignancy for whom biological samples and clinical data are available may be included in this study, after obtaining informed consent. The primary objective is to improve our knowledge of the pathogenic mechanisms driving malignant disorders and transformation. The secondary objectives aim to improve diagnosis and stratification of onco-hematological patients and study drug response at preclinical level. After signing informed consent to the study, each patient will donate part of the samples (peripheral blood, bone marrow, biopsies) collected as per routine clinical practice for the management of their disease.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2000
- Participant is willing and able to give informed consent for participation in the study
- Male or Female, aged >18 years
- Patients with histologically confirmed diagnosis of one of the following haematological diseases: monoclonal gammopathy of undetermined significance (MGUS), idiopathic cytopenia of undetermined significance (ICUS), clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or hematological malignancies: Peripheral T-cell Lymphomas (PTCL), B- and T-Lymphoblastic Leukemias / Lymphomas (ALL), Burkitt Lymphoma (BL), B and T cell lymphoma, Acute Myeloid Leukemia (AML), Myeloproliferative Disease (Polycythemia Vera (PV), Essential Thrombocythemia (ET), Monocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Myelofibrosis, Myelodysplasia (MDS) including Macrocytic Anemia, Sideroblastic Anemia and Non-Neoplastic Hematologic Disease, Systemic Mastocytosis, Multiple Myeloma (MM), Plasma Cell Disease.
- Available clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures);
- For the retrospective part of the study: availability of biological samples collected for routine diagnostics/therapeutic procedures and stored as appropriate, per laboratory standard procedures.
- Patients included in clinical trials may be enrolled in this explorative study, except where otherwise clearly indicated in the experimental protocol
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description hematologic disorder or malignancy clinical data and sample collection -
- Primary Outcome Measures
Name Time Method haematologic diseases characterization up to 5 years To improve our knowledge of the pathogenic mechanisms driving malignant disorders and transformation in different subgroups, defined by molecular, metabolic, proteomic, imaging, preclinical and clinical data integration
- Secondary Outcome Measures
Name Time Method Minimal residual disease (MRD) up to 5 years To investigate recurrence/minimal residual disease patterns after treatments
Ex vivo Response/resistance up to 5 years To define response/resistance to ex vivo drug treatments;
toxicity biomarkers identification up to 5 years To identify biomarkers of drug-related toxicity;
Prognostic and early diagnostic biomarkers up to 5 years To identify novel biomarkers for early diagnosis (e.g. predictive of transformation from a pre-malignant to an overt malignant phase) and prognosis.
identification of circulating and tissue molecular markers. up to 5 years To improve the diagnostic work-up of haematological disease, thus enlarging the fraction of patients suitable for curative treatments through the identification of circulating and tissue molecular markers.
technological advancement up to 5 years To provide a technological advancement potentially applicable to the national health system, when properly validated in appropriate patients' subgroups.
Biological and molecular features up to 5 years To investigate association between biological and molecular features with patient's clinical features.
Trial Locations
- Locations (26)
Ospedale Ca' Foncello Treviso
🇮🇹Treviso, Italy
IRCSS Istituto Tumori
🇮🇹Bari, Italy
IRCCS Fondazione Policlinico Universitario A. Gemelli
🇮🇹Roma, Italy
AOU Città della Salute e della scienza di Torino
🇮🇹Torino, TO, Italy
Istituto Nazionale Tumori Di Napoli Irccs
🇮🇹Napoli, Italy
UO Hematology, Ospedale S. Maria delle Croci
🇮🇹Ravenna, Italy
Arcispedale S. Maria Nuova - AUSL IRCCS
🇮🇹Reggio Emilia, Italy
UO Hematology Ospedale Infermi
🇮🇹Rimini, Italy
AOU" San Giovanni di Dio e Ruggi d'Aragona"
🇮🇹Salerno, Italy
AO Ordine Mauriziano
🇮🇹Torino, Italy
Irst Irccs
🇮🇹Meldola, FC, Italy
A.O.U. Consorziale policlinico Giovanni XXIII di Bari
🇮🇹Bari, Italy
Ospedale A. Perrino
🇮🇹Brindisi, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milano, Italy
Irccs Iov
🇮🇹Padova, Italy
Centro di Riferimento Oncologico - CRO Irccs
🇮🇹Aviano, Italy
AORN " A. Cardarelli"
🇮🇹Napoli, Italy
P.O. Santo Spirito
🇮🇹Pescara, Italy
C.R.O.B. - I.R.C.C.S.
🇮🇹Rionero In Vulture, Potenza, Italy
Ospedale Santa Croce e Carle
🇮🇹Cuneo, Italy
IRCCS Osp. Policlinico San Martino
🇮🇹Genova, Italy
Istituto Giannina Gaslini
🇮🇹Genova, Italy
IEO
🇮🇹Milano, Italy
AUO San Luigi Gonzaga
🇮🇹Orbassano, Italy
AOU "P. Giaccone"
🇮🇹Palermo, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy